

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  25D0866582	<b>(X3) Date Survey Completed</b>  10/02/2023
<b>Name of Provider or Supplier</b>  Memphis Pathology Laboratory DbA Ael-Jackson Ms	<b>Street Address, City, State</b>  1020 River Oaks Drive Suite 320, Flowood, MS	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2000</b>	<p>ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801</p> <p>Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994.</p> <p>This CONDITION is not met as evidenced by: Based on review of the Centers for Medicare and Medicaid Services (CMS) data system for proficiency testing, the laboratory's proficiency testing (PT) records for 2022 and 2023, and the laboratory's monthly patient test counts, the laboratory failed to enroll in an HHS approved proficiency testing program for routine chemistry testing, performed on the Alfa Wassermann ACE Alera chemistry analyzer, for 2 of 3 events for 2023, for serum qualitative human chorionic gonadotropin (HCG) testing, performed on the Fisher Healthcare Sure-Vue Serum/Urine HCG Stat test, for 2 of 3 events of 2023, and for complete blood count (CBC) testing, performed on the CDS Medonic M-Series hematology analyzer, for 1 of 3 events of 2023. Findings include: 1. Review of the CMS data system for proficiency testing and the laboratory's PT records for 2022 and 2023 revealed no documentation of the performance of proficiency testing for the following tests listed in Subpart I: a) Routine chemistry tests, performed on the Alfa Wassermann ACE Alera chemistry analyzer, for Events 2 and 3 of 2023 (2 of 3 events in 2023), including albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, calcium, chloride, high-density lipoprotein (HDL) cholesterol, total cholesterol, creatinine, glucose, potassium, sodium, total protein, triglycerides, blood urea nitrogen. b) Serum</p>

qualitative HCG test, performed on the Fisher Healthcare Sure-View Serum/Urine HCG Stat test, for Events 2 and 3 of 2023 (2 of 3 events in 2023). c) CBC testing, performed on the CDS Medonic M-Series hematology analyzer, for Event 2 of 2023 (1 of 3 events for 2023). 2. Review of the laboratory's monthly test counts for 2023 revealed the patient test count for routine chemistry tests listed in Subpart I, serum qualitative HCG test, and CBC tests were as follows: a) The patient test count for routine chemistry tests, listed in Subpart I, from 2/1/2023 through 9/30/2023 was 14,039. The last routine chemistry proficiency testing performed in 2023 was performed on 1/12/2023. b) The patient test count for serum qualitative HCG from 2/1/2023 through 9/30/2023 was 55. The last serum qualitative HCG proficiency testing performed in 2023 was performed on 1/12/2023. c) The patient test count for CBC tests from 4/1/2023 through 9/30/2023 was 5,752. The last CBC proficiency testing performed in 2023 was performed on 3/9/2023.